PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Inclusion Criteria:

* Adult male or female patients with histologically or cytologically confirmed renal cell cancer (RCC) with a component of clear cell subtype and evidence of metastasis
* Evidence of unidimensionally measurable disease
* Prior therapy: Part I: Having received 1 to 3 prior systemic regimens for treatment of mRCC
* Part II: Evidence of disease progression following 1 prior regimen administered as 1st line therapy for mRCC. The prior regimen must have contained one of the following: VEGFR2 tyrosine kinase inhibitor (TKI) or other anti VEGF \[Vascular Endothelial Growth Factor\] compounds, such as bevacizumab
* adequate bone marrow, liver and renal function

Exclusion Criteria:

Part I:

* Intolerant to prior AG 013736 therapy or prior treatment with compounds which contain the core platform antibody as PF 04856884

Part II:

* Prior AG 013736 therapy, more than one systemic first-line regimen for the treatment of mRCC and prior treatment with compounds which contain the core platform antibody as PF 04856884
* major surgery \<4 weeks or radiation therapy \<2 weeks prior to start of therapy
* clinically significant gastrointestinal abnormalities
* current use or anticipated need for drugs that are known potent CYP3A4 inhibitors and drugs that are known CYP3A4 or CYP1A2 inducers
* history of bleeding diathesis or coagulopathy
* Grade 3 or greater hemorrhage from any cause \<4 weeks prior to screening;
* hemoptysis \>½ teaspoon of blood per day within 2 weeks prior to screening.